Skip to content
MamaGLP — home

Evidence review

GLP-1s and Pregnancy: What the Data Actually Shows

Can you take a GLP-1 while pregnant, or did you conceive while on one? What the labels say, and what the 2026 data on already-exposed pregnancies shows.

Written by Camila Rael, editora mom, not a clinician treating you

Every medical claim is cited to its primary source — the clinical trial or the FDA label — so you can open it and check it yourself. No one on this team is your healthcare professional. What follows is friendly information, never medical advice.

On this page

The question that brought you here

Maybe you're planning ahead and want to know when to stop. Or maybe you already have a positive test in your hand and your heart racing. Both questions deserve a straight answer, so here it is: GLP-1s aren't used in pregnancy, so you stop as soon as you know — but if you already conceived while on one, the human data we have so far are more reassuring than the label alone suggests. This is information, not medical advice; the decision is always with your clinician.

Why the label says stop

The Wegovy label is direct: weight loss offers no benefit to someone who's pregnant and may cause fetal harm, so the drug should be discontinued once pregnancy is recognized1. That instruction comes from animal studies, where GLP-1 exposure has been linked to lower fetal growth and skeletal, visceral, and embryonic problems2. There's no body of human trial data to weigh against that signal — no pharmaceutical company runs a pregnancy safety trial on a weight-loss drug — so obstetric medicine defaults to caution when the animal signal exists and the human evidence is thin.

What actually calms things down

Because early accidental exposure isn't rare anymore, two research teams pooled real-world outcomes in 2026. One combined six studies and 43,577 women exposed around conception, and found no significant difference in the risk of major congenital malformations versus unexposed pregnancies3. The other combined seven cohort studies, more than 40,000 exposed pregnancies, and reached the same conclusion — no statistically significant increase in malformations, stillbirth, miscarriage, or preterm birth4. Neither team calls this proof of safety; both call for more prospective data34. But "we found no signal across tens of thousands of pregnancies" reads very differently at 2am than "we don't know." A broader 2026 review of this drug class's safety across preconception, pregnancy, and lactation reached an equally measured conclusion — reassuring so far, not fully settled5.

If you're already pregnant

  1. Stop the medication. Don't take another dose while you sort out next steps — the one thing every source agrees on1.
  2. Call your OB soon. Tell her exactly what you were taking and when your last dose was. This isn't a new conversation for her.
  3. Don't panic. The pooled data don't show a significantly higher risk from an early accidental exposure34.
  4. Start your normal prenatal care — folate, your first visit, whatever your OB recommends. The goal shifts from weight loss to a healthy pregnancy.

If you're still planning

If pregnancy hasn't happened yet, the calmer version is the planned one: contraception while you're still on the medication, a deliberate stop per your specific drug's label, and then trying. Our guide to GLP-1s and fertility covers the full washout window and what happens after you stop, and if PCOS is part of your story, can GLP-1 help PCOS? explains why ovulation sometimes comes back faster than expected.

How much to trust each claim

Don't give equal weight to the two ideas on this page. "Don't use a GLP-1 in pregnancy" is the settled one — it's on the label, backed by animal data, and weight loss offers a pregnancy nothing12. "An early accidental exposure probably didn't hurt your baby" is the newer, still-improving one — real, pooled across tens of thousands of pregnancies, but still observational, and the researchers themselves say so34. I'm not going to smooth over that difference for you. It's the gap between "trust this completely" and "this is the best we have right now, and it's genuinely reassuring."

Frequently asked questions

Is it dangerous that I got pregnant while taking a GLP-1?

The reassuring finding: two 2026 meta-analyses pooling tens of thousands of exposed pregnancies did not find a statistically significant increase in major birth defects from early GLP-1 exposure. The label's concern comes from animal studies, not this human data. The standard advice is still to stop the medication as soon as you know and call your OB promptly.

What should I do if I find out I'm pregnant while on a GLP-1?

Stop the medication, then contact your OB or prescriber and tell them exactly what you were taking, at what dose, and when your last dose was. Start your normal prenatal care — folate, your first visit. The goal shifts from weight loss to a healthy pregnancy.

Can I keep taking a GLP-1 if it's still helping me lose weight early in pregnancy?

No — GLP-1s aren't used in pregnancy. Weight loss offers a pregnancy no benefit, and animal studies showed possible fetal harm, so labels advise stopping once pregnancy is recognized. Weight management in pregnancy is handled differently, with your obstetric provider.

References

  1. Novo Nordisk Inc. (2026). WEGOVY (semaglutide) injection and tablets — Prescribing Information, sections 8.1 Pregnancy and 8.3 Females and Males of Reproductive Potential (label revised 6/2026). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. Drummond RF, Seif KE, Reece EA (2025). Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. American Journal of Obstetrics and Gynecology. https://pubmed.ncbi.nlm.nih.gov/39181497/
  3. Liu X, Xiong B, Yang R, Wang H, Liu Y (2026). Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis. Endocrine Connections. https://pubmed.ncbi.nlm.nih.gov/42447044/
  4. Uysal N, Horoz E, Gungor M, et al. (2026). Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/42420519/
  5. Ozbek L, Shah E, Al-Shiab R, et al. (2026). Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/41885132/

Friendly information, not a prescription. Everything on MamaGLP is here to help you understand your options and ask better questions — it is not a diagnosis, not a treatment plan, and not a nudge to start or stop anything. Only a licensed healthcare professional who knows your history and your goals can tell you what is right for you, so please talk with one before acting on a single word of this.